pmid
stringlengths 8
12
| sentence
stringlengths 59
1.08k
| cancer_type
stringclasses 3
values | gene
dict | cancer
dict | CGE
stringclasses 2
values | CCS
stringclasses 3
values | PT
stringclasses 3
values | IGE
stringclasses 4
values | expression_change_keyword_1
dict | expression_change_keyword_2
dict |
|---|---|---|---|---|---|---|---|---|---|---|
12855632.s0 | Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. | ovarian | {
"name": "claudin-4",
"pos": [
38,
46
]
} | {
"name": "ovarian cystadenomas",
"pos": [
106,
125
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpressed",
"pos": [
63,
75
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
63,
75
],
"type": "Positive_regulation"
} |
12855632.s0 | Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. | ovarian | {
"name": "claudin-3",
"pos": [
24,
32
]
} | {
"name": "ovarian cystadenomas",
"pos": [
106,
125
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpressed",
"pos": [
63,
75
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
63,
75
],
"type": "Positive_regulation"
} |
12855632.s8 | Although expressed at low levels in some normal human tissues, including the ovary, CLDN3 and CLDN4 are highly up-regulated in epithelial ovarian cancers of all subtypes. | ovarian | {
"name": "CLDN4",
"pos": [
94,
98
]
} | {
"name": "epithelial ovarian cancers",
"pos": [
127,
152
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "up-regulated",
"pos": [
111,
122
],
"type": "Positive_regulation"
} |
12855632.s8 | Although expressed at low levels in some normal human tissues, including the ovary, CLDN3 and CLDN4 are highly up-regulated in epithelial ovarian cancers of all subtypes. | ovarian | {
"name": "CLDN3",
"pos": [
84,
88
]
} | {
"name": "epithelial ovarian cancers",
"pos": [
127,
152
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "up-regulated",
"pos": [
111,
122
],
"type": "Positive_regulation"
} |
12855632.s12 | These results show that CLDN3 and CLDN4 are frequently up-regulated in ovarian tumors and cell lines and may represent novel markers for this disease. | ovarian | {
"name": "CLDN3",
"pos": [
24,
28
]
} | {
"name": "ovarian tumors",
"pos": [
71,
84
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "up-regulated",
"pos": [
55,
66
],
"type": "Positive_regulation"
} |
12855632.s12 | These results show that CLDN3 and CLDN4 are frequently up-regulated in ovarian tumors and cell lines and may represent novel markers for this disease. | ovarian | {
"name": "CLDN4",
"pos": [
34,
38
]
} | {
"name": "ovarian tumors",
"pos": [
71,
84
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "up-regulated",
"pos": [
55,
66
],
"type": "Positive_regulation"
} |
12684414.s0 | Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. | ovarian | {
"name": "centrosome kinase BTAK/Aurora-A",
"pos": [
33,
63
]
} | {
"name": "ovarian cancer",
"pos": [
74,
87
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpression",
"pos": [
15,
28
],
"type": "Gene_expression"
} | {
"name": "overexpression",
"pos": [
15,
28
],
"type": "Positive_regulation"
} |
12684414.s0 | Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. | ovarian | {
"name": "centrosome kinase BTAK/Aurora-A",
"pos": [
33,
63
]
} | {
"name": "ovarian cancer",
"pos": [
74,
87
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "Activation",
"pos": [
0,
9
],
"type": "Positive_regulation"
} |
18349819.s2 | We have previously shown that the E3 ubiquitin ligase, EDD, a regulator of DNA damage responses, is amplified and overexpressed in serous ovarian carcinoma. | ovarian | {
"name": "EDD",
"pos": [
55,
57
]
} | {
"name": "ovarian carcinoma",
"pos": [
138,
154
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpressed",
"pos": [
114,
126
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
114,
126
],
"type": "Positive_regulation"
} |
18349819.s5 | Although EDD expression was not directly correlated with relative cisplatin sensitivity of ovarian cancer cell lines, sensitivity to cisplatin was partially restored in platinum-resistant A2780-cp70 ovarian cancer cells following siRNA-mediated knockdown of EDD expression. | ovarian | {
"name": "EDD",
"pos": [
258,
260
]
} | {
"name": "ovarian cancer",
"pos": [
91,
104
]
} | decreased | unidentifiable | {
"name": "expression",
"pos": [
262,
271
],
"type": "Gene_expression"
} | {
"name": "knockdown",
"pos": [
245,
253
],
"type": "Negative_regulation"
} |
||
11601039.s7 | In patients with recurrence of ovary tumor, the IAP levels was increased to compare with the health women (P < 0.01), the incidence of the abnormal value was 100%. | ovarian | {
"name": "IAP",
"pos": [
48,
50
]
} | {
"name": "ovary tumor",
"pos": [
31,
41
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "increased",
"pos": [
63,
71
],
"type": "Positive_regulation"
} |
8672936.s0 | [Overexpression of p53 protein in ovarian carcinomas: correlation with histopathologic data and clinical course]. | ovarian | {
"name": "p53 protein",
"pos": [
19,
29
]
} | {
"name": "ovarian carcinomas",
"pos": [
34,
51
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "[Overexpression",
"pos": [
0,
14
],
"type": "Gene_expression"
} | {
"name": "[Overexpression",
"pos": [
0,
14
],
"type": "Positive_regulation"
} |
8672936.s1 | The accumulation of p53 protein was analysed immunohistochemically in ovarian cancer and correlated with clinical data to further clarify the role of p53 mutations for prognosis in these patients. | ovarian | {
"name": "p53 protein",
"pos": [
20,
30
]
} | {
"name": "ovarian cancer",
"pos": [
70,
83
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "accumulation",
"pos": [
4,
15
],
"type": "Positive_regulation"
} |
21957230.s11 | Increased p130cas expression is associated with poor clinical outcome in human ovarian carcinoma, and p130cas gene silencing decreases tumor growth through stimulation of apoptotic and autophagic cell death. | ovarian | {
"name": "p130cas",
"pos": [
10,
16
]
} | {
"name": "ovarian carcinoma",
"pos": [
79,
95
]
} | increased | normalTOcancer | causality | unchanged | {
"name": "expression",
"pos": [
18,
27
],
"type": "Gene_expression"
} | {
"name": "Increased",
"pos": [
0,
8
],
"type": "Positive_regulation"
} |
18386461.s0 | Concentrations of follicle stimulating hormone are increased in ovarian tumor fluid: implications for the management of ovarian cancer. | ovarian | {
"name": "follicle stimulating hormone",
"pos": [
18,
45
]
} | {
"name": "ovarian cancer",
"pos": [
120,
133
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "increased",
"pos": [
51,
59
],
"type": "Positive_regulation"
} |
14516936.s3 | BRCA1 expression is decreased or absent in a significant proportion of sporadic breast and ovarian cancers, suggesting a wider role in these tumor types. | ovarian | {
"name": "BRCA1",
"pos": [
0,
4
]
} | {
"name": "ovarian cancers",
"pos": [
91,
105
]
} | decreased | normalTOcancer | observation | unchanged | {
"name": "expression",
"pos": [
6,
15
],
"type": "Gene_expression"
} | {
"name": "decreased",
"pos": [
20,
28
],
"type": "Negative_regulation"
} |
17673518.s3 | Epidermal growth factor (EGF) and hepatocyte growth factor (HGF) are often both overexpressed and contribute to the growth of ovarian cancer by activating autocrine pathways. | ovarian | {
"name": "EGF",
"pos": [
25,
27
]
} | {
"name": "ovarian cancer",
"pos": [
126,
139
]
} | increased | normalTOcancer | causality | unchanged | {
"name": "overexpressed",
"pos": [
80,
92
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
80,
92
],
"type": "Positive_regulation"
} |
17673518.s3 | Epidermal growth factor (EGF) and hepatocyte growth factor (HGF) are often both overexpressed and contribute to the growth of ovarian cancer by activating autocrine pathways. | ovarian | {
"name": "hepatocyte growth factor",
"pos": [
34,
57
]
} | {
"name": "ovarian cancer",
"pos": [
126,
139
]
} | increased | normalTOcancer | causality | unchanged | {
"name": "overexpressed",
"pos": [
80,
92
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
80,
92
],
"type": "Positive_regulation"
} |
17673518.s3 | Epidermal growth factor (EGF) and hepatocyte growth factor (HGF) are often both overexpressed and contribute to the growth of ovarian cancer by activating autocrine pathways. | ovarian | {
"name": "Epidermal growth factor",
"pos": [
0,
22
]
} | {
"name": "ovarian cancer",
"pos": [
126,
139
]
} | increased | normalTOcancer | causality | unchanged | {
"name": "overexpressed",
"pos": [
80,
92
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
80,
92
],
"type": "Positive_regulation"
} |
17673518.s3 | Epidermal growth factor (EGF) and hepatocyte growth factor (HGF) are often both overexpressed and contribute to the growth of ovarian cancer by activating autocrine pathways. | ovarian | {
"name": "HGF",
"pos": [
60,
62
]
} | {
"name": "ovarian cancer",
"pos": [
126,
139
]
} | increased | normalTOcancer | causality | unchanged | {
"name": "overexpressed",
"pos": [
80,
92
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
80,
92
],
"type": "Positive_regulation"
} |
11877386.s10 | According to this mechanism the deregulation of the BRCA1 transcription in cancer, resulting in a higher proportion of translationally inhibited transcripts containing 5'-UTRb, contributes to the decrease in the BRCA1 protein observed in sporadic breast and ovarian cancers. | ovarian | {
"name": "BRCA1 protein",
"pos": [
212,
224
]
} | {
"name": "ovarian cancers",
"pos": [
258,
272
]
} | decreased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "decrease",
"pos": [
196,
203
],
"type": "Negative_regulation"
} |
1358427.s1 | Amplification or overexpression of the c-erbB-2 gene have been reported to correlate with poor patient prognosis in human breast, gastric, and ovarian cancer. | ovarian | {
"name": "c-erbB-2 gene",
"pos": [
39,
51
]
} | {
"name": "ovarian cancer",
"pos": [
143,
156
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpression",
"pos": [
17,
30
],
"type": "Gene_expression"
} | {
"name": "overexpression",
"pos": [
17,
30
],
"type": "Positive_regulation"
} |
10408832.s7 | We propose that, in the ovarian tumour microenvironment, interaction between tumour cells and fibroblasts may enhance fibroblast production of the proMMP-2 and TIMP-2. | ovarian | {
"name": "proMMP-2",
"pos": [
147,
154
]
} | {
"name": "ovarian tumour",
"pos": [
24,
37
]
} | increased | unidentifiable | {
"name": "production",
"pos": [
129,
138
],
"type": "Gene_expression"
} | {
"name": "enhance",
"pos": [
110,
116
],
"type": "Positive_regulation"
} |
||
10408832.s7 | We propose that, in the ovarian tumour microenvironment, interaction between tumour cells and fibroblasts may enhance fibroblast production of the proMMP-2 and TIMP-2. | ovarian | {
"name": "TIMP-2",
"pos": [
160,
165
]
} | {
"name": "ovarian tumour",
"pos": [
24,
37
]
} | increased | unidentifiable | {
"name": "production",
"pos": [
129,
138
],
"type": "Gene_expression"
} | {
"name": "enhance",
"pos": [
110,
116
],
"type": "Positive_regulation"
} |
||
10408832.s8 | Collagen I, also present in the ovarian tumours, then induces these fibroblasts to activate proMMP-2 even in the presence of TIMP-2. | ovarian | {
"name": "proMMP-2",
"pos": [
92,
99
]
} | {
"name": "ovarian tumours",
"pos": [
32,
46
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "activate",
"pos": [
83,
90
],
"type": "Positive_regulation"
} |
||
19181441.s1 | We previously showed that the expressing level of FSH receptor (FSHR) increased from ovarian epithelial inclusions (OEIs) to benign ovarian epithelial tumors (OETs) and to borderline OETs, whereas FSHR levels decreased with an increase in carcinoma grade. | ovarian | {
"name": "FSHR",
"pos": [
64,
67
]
} | {
"name": "ovarian epithelial tumors",
"pos": [
132,
156
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "increased",
"pos": [
70,
78
],
"type": "Positive_regulation"
} |
||
19181441.s1 | We previously showed that the expressing level of FSH receptor (FSHR) increased from ovarian epithelial inclusions (OEIs) to benign ovarian epithelial tumors (OETs) and to borderline OETs, whereas FSHR levels decreased with an increase in carcinoma grade. | ovarian | {
"name": "FSH receptor",
"pos": [
50,
61
]
} | {
"name": "ovarian epithelial tumors",
"pos": [
132,
156
]
} | increased | unidentifiable | {
"name": "expressing",
"pos": [
30,
39
],
"type": "Gene_expression"
} | {
"name": "increased",
"pos": [
70,
78
],
"type": "Positive_regulation"
} |
||
19181441.s1 | We previously showed that the expressing level of FSH receptor (FSHR) increased from ovarian epithelial inclusions (OEIs) to benign ovarian epithelial tumors (OETs) and to borderline OETs, whereas FSHR levels decreased with an increase in carcinoma grade. | ovarian | {
"name": "FSHR",
"pos": [
64,
67
]
} | {
"name": "ovarian epithelial tumors",
"pos": [
132,
156
]
} | increased | unidentifiable | {
"name": "expressing",
"pos": [
30,
39
],
"type": "Gene_expression"
} | {
"name": "increased",
"pos": [
70,
78
],
"type": "Positive_regulation"
} |
||
16217764.s4 | IL-18 and FGF-2 proteins were significantly elevated in tumor tissues (p<0.04) and sera (p<0.05) from patients with ovarian cancer. | ovarian | {
"name": "IL-18",
"pos": [
0,
4
]
} | {
"name": "ovarian cancer",
"pos": [
116,
129
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "elevated",
"pos": [
44,
51
],
"type": "Positive_regulation"
} |
16217764.s4 | IL-18 and FGF-2 proteins were significantly elevated in tumor tissues (p<0.04) and sera (p<0.05) from patients with ovarian cancer. | ovarian | {
"name": "FGF-2 proteins",
"pos": [
10,
23
]
} | {
"name": "ovarian cancer",
"pos": [
116,
129
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "elevated",
"pos": [
44,
51
],
"type": "Positive_regulation"
} |
10342830.s17 | In addition, the higher PA1 cell responsiveness to endogenous compared with exogenous activin, suggests that activin overexpression in PA1 cells may up-regulate an activin signaling component, or down-regulate an activin signaling inhibitor. | ovarian | {
"name": "activin",
"pos": [
164,
170
]
} | {
"name": "PA1",
"pos": [
24,
26
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "up-regulate",
"pos": [
149,
159
],
"type": "Positive_regulation"
} |
||
10342830.s17 | In addition, the higher PA1 cell responsiveness to endogenous compared with exogenous activin, suggests that activin overexpression in PA1 cells may up-regulate an activin signaling component, or down-regulate an activin signaling inhibitor. | ovarian | {
"name": "activin",
"pos": [
109,
115
]
} | {
"name": "PA1",
"pos": [
24,
26
]
} | increased | unidentifiable | {
"name": "overexpression",
"pos": [
117,
130
],
"type": "Gene_expression"
} | {
"name": "overexpression",
"pos": [
117,
130
],
"type": "Positive_regulation"
} |
||
7763262.s3 | Blocking of IL-1 alpha activity in HOC-7 cells with either IL-1 receptor antagonist (IL-1ra) or a neutralizing antibody directed against IL-1 alpha resulted in a dose-dependent decrease of IL-8 release by ATRA, TNF-alpha and IL-1 alpha treated HOC-7 cells. | ovarian | {
"name": "IL-1 alpha",
"pos": [
12,
21
]
} | {
"name": "HOC-7",
"pos": [
35,
39
]
} | decreased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "Blocking",
"pos": [
0,
7
],
"type": "Negative_regulation"
} |
||
11026599.s5 | These results indicate that long-term NF treatment induces ovarian tumors in mice, possibly by continuous stimulation with gonadotropins such as LH via a negative-feedback phenomenon secondary to ovarian atrophy (as the tumor-induction mechanism), although we could not completely rule out a genotoxic mechanism. | ovarian | {
"name": "LH",
"pos": [
145,
146
]
} | {
"name": "ovarian tumors",
"pos": [
59,
72
]
} | increased | normalTOcancer | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "stimulation",
"pos": [
106,
116
],
"type": "Positive_regulation"
} |
1696386.s2 | Four out of the twelve cancer tissue specimens, one specimen of cancer ascites cells and the NIH: OVCAR-3 cancer cell line showed elevated amplification of c-Ki-ras, as compared to the human fibroblast cell line FS4 and normal ovarian tissues. | ovarian | {
"name": "c-Ki-ras",
"pos": [
156,
163
]
} | {
"name": "OVCAR-3",
"pos": [
98,
104
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "elevated",
"pos": [
130,
137
],
"type": "Positive_regulation"
} |
17409410.s0 | Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. | ovarian | {
"name": "Six1",
"pos": [
0,
3
]
} | {
"name": "ovarian carcinoma",
"pos": [
23,
39
]
} | increased | normalTOcancer | causality | unchanged | {
"name": "overexpression",
"pos": [
5,
18
],
"type": "Gene_expression"
} | {
"name": "overexpression",
"pos": [
5,
18
],
"type": "Positive_regulation"
} |
17409410.s2 | Here, we show that the developmental regulator Six1 is overexpressed in ovarian carcinoma cell lines (OCC) compared with normal ovarian surface epithelium. | ovarian | {
"name": "Six1",
"pos": [
47,
50
]
} | {
"name": "ovarian carcinoma",
"pos": [
72,
88
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpressed",
"pos": [
55,
67
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
55,
67
],
"type": "Positive_regulation"
} |
17409410.s4 | In addition, Six1 overexpression renders OCC resistant to tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-mediated apoptosis, and Six1 knockdown in the TRAIL-resistant SKOV3 ovarian carcinoma line dramatically sensitizes the cells to TRAIL. | ovarian | {
"name": "Six1",
"pos": [
146,
149
]
} | {
"name": "ovarian carcinoma",
"pos": [
190,
206
]
} | decreased | cancerTOnormal | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "knockdown",
"pos": [
151,
159
],
"type": "Negative_regulation"
} |
17409410.s4 | In addition, Six1 overexpression renders OCC resistant to tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-mediated apoptosis, and Six1 knockdown in the TRAIL-resistant SKOV3 ovarian carcinoma line dramatically sensitizes the cells to TRAIL. | ovarian | {
"name": "Six1",
"pos": [
13,
16
]
} | {
"name": "ovarian carcinoma",
"pos": [
190,
206
]
} | increased | normalTOcancer | causality | unidentifiable | {
"name": "overexpression",
"pos": [
18,
31
],
"type": "Gene_expression"
} | {
"name": "overexpression",
"pos": [
18,
31
],
"type": "Positive_regulation"
} |
17409410.s6 | Six1 was overexpressed in 50% of the early-stage (stage I) and 63% of the late-stage (stages II, III, and IV) ovarian carcinomas examined, with late-stage carcinomas expressing approximately 3-fold higher Six1 mRNA levels on average compared with early-stage tumors. | ovarian | {
"name": "Six1",
"pos": [
0,
3
]
} | {
"name": "ovarian carcinomas",
"pos": [
110,
127
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpressed",
"pos": [
9,
21
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
9,
21
],
"type": "Positive_regulation"
} |
17276501.s2 | We have previously shown that acquisition of cisplatin resistance by OAW42-R ovarian carcinoma cells was associated with the loss of ERK activation in response to cisplatin. | ovarian | {
"name": "ERK",
"pos": [
133,
135
]
} | {
"name": "ovarian carcinoma",
"pos": [
77,
93
]
} | decreased | cancerTOnormal | observation | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "loss",
"pos": [
125,
128
],
"type": "Negative_regulation"
} |
11032026.s0 | Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to alpha-folate receptor overexpression. | ovarian | {
"name": "caveolin-1",
"pos": [
18,
27
]
} | {
"name": "ovarian carcinoma",
"pos": [
49,
65
]
} | decreased | unidentifiable | {
"name": "expression",
"pos": [
29,
38
],
"type": "Gene_expression"
} | {
"name": "Downmodulation",
"pos": [
0,
13
],
"type": "Negative_regulation"
} |
||
11032026.s0 | Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to alpha-folate receptor overexpression. | ovarian | {
"name": "alpha-folate receptor",
"pos": [
90,
110
]
} | {
"name": "ovarian carcinoma",
"pos": [
49,
65
]
} | increased | unidentifiable | {
"name": "overexpression",
"pos": [
112,
125
],
"type": "Gene_expression"
} | {
"name": "overexpression",
"pos": [
112,
125
],
"type": "Positive_regulation"
} |
||
11032026.s5 | SKOV3, but not two alphaFR-negative non-ovarian cell lines, exhibited down-regulation of cav-1 expression following stable alphaFR cDNA transfection. | ovarian | {
"name": "alphaFR cDNA",
"pos": [
123,
134
]
} | {
"name": "SKOV3",
"pos": [
0,
4
]
} | increased | unidentifiable | {
"name": "transfection",
"pos": [
136,
147
],
"type": "Gene_expression"
} | {
"name": "transfection",
"pos": [
136,
147
],
"type": "Positive_regulation"
} |
||
11032026.s5 | SKOV3, but not two alphaFR-negative non-ovarian cell lines, exhibited down-regulation of cav-1 expression following stable alphaFR cDNA transfection. | ovarian | {
"name": "cav-1",
"pos": [
89,
93
]
} | {
"name": "SKOV3",
"pos": [
0,
4
]
} | decreased | unidentifiable | {
"name": "expression",
"pos": [
95,
104
],
"type": "Gene_expression"
} | {
"name": "down-regulation",
"pos": [
70,
84
],
"type": "Negative_regulation"
} |
||
11032026.s6 | Conversely, cav-1 transfection in IGROV1 cells led to downregulated alphaFR expression, together with formation of caveolar structures and reduction of growth capability. | ovarian | {
"name": "cav-1",
"pos": [
12,
16
]
} | {
"name": "IGROV1",
"pos": [
34,
39
]
} | increased | cancerTOnormal | causality | unidentifiable | {
"name": "transfection",
"pos": [
18,
29
],
"type": "Gene_expression"
} | {
"name": "transfection",
"pos": [
18,
29
],
"type": "Positive_regulation"
} |
11032026.s7 | Moreover, cav-1 expression was induced in IGROV1 cells by transfection with intracellular anti-alphaFR antibodies to downmodulate alphaFR expression. | ovarian | {
"name": "cav-1",
"pos": [
10,
14
]
} | {
"name": "IGROV1",
"pos": [
42,
47
]
} | increased | unidentifiable | {
"name": "expression",
"pos": [
16,
25
],
"type": "Gene_expression"
} | {
"name": "induced",
"pos": [
31,
37
],
"type": "Positive_regulation"
} |
||
11032026.s7 | Moreover, cav-1 expression was induced in IGROV1 cells by transfection with intracellular anti-alphaFR antibodies to downmodulate alphaFR expression. | ovarian | {
"name": "alphaFR",
"pos": [
130,
136
]
} | {
"name": "IGROV1",
"pos": [
42,
47
]
} | decreased | unidentifiable | {
"name": "expression",
"pos": [
138,
147
],
"type": "Gene_expression"
} | {
"name": "downmodulate",
"pos": [
117,
128
],
"type": "Negative_regulation"
} |
||
11032026.s7 | Moreover, cav-1 expression was induced in IGROV1 cells by transfection with intracellular anti-alphaFR antibodies to downmodulate alphaFR expression. | ovarian | {
"name": "cav-1",
"pos": [
10,
14
]
} | {
"name": "IGROV1",
"pos": [
42,
47
]
} | increased | unidentifiable | {
"name": "expression",
"pos": [
16,
25
],
"type": "Gene_expression"
} | {
"name": "induced",
"pos": [
31,
37
],
"type": "Positive_regulation"
} |
||
22027746.s12 | Attenuating hypoxia-inducible factor (HIF)-1α expression via small interference RNA resulted in a significantly decreased hCG expression in OVCAR-3, which indicated that the effect of hypoxia on hCG expression was mediated through HIF-1α. | ovarian | {
"name": "hCG",
"pos": [
122,
124
]
} | {
"name": "OVCAR-3",
"pos": [
140,
146
]
} | decreased | unidentifiable | {
"name": "expression",
"pos": [
126,
135
],
"type": "Gene_expression"
} | {
"name": "decreased",
"pos": [
112,
120
],
"type": "Negative_regulation"
} |
||
22027746.s14 | Expression level of vascular marker and HIF-1α in OVCAR-3 increased in response to hCG treatment in a dose-dependent manner. | ovarian | {
"name": "HIF-1α",
"pos": [
40,
45
]
} | {
"name": "OVCAR-3",
"pos": [
50,
56
]
} | increased | unidentifiable | {
"name": "Expression",
"pos": [
0,
9
],
"type": "Gene_expression"
} | {
"name": "increased",
"pos": [
58,
66
],
"type": "Positive_regulation"
} |
||
20657552.s4 | Increased expression of CD146, a cell adhesion molecule, has been reported to be closely associated with an advanced stage of malignant melanoma, prostate cancer, and ovarian cancer. | ovarian | {
"name": "CD146",
"pos": [
24,
28
]
} | {
"name": "ovarian cancer",
"pos": [
167,
180
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "expression",
"pos": [
10,
19
],
"type": "Gene_expression"
} | {
"name": "Increased",
"pos": [
0,
8
],
"type": "Positive_regulation"
} |
9458352.s4 | IL-1 and CDDP treatment induced p53 protein in NIH:OVCAR-3 tumor cells. | ovarian | {
"name": "p53 protein",
"pos": [
32,
42
]
} | {
"name": "OVCAR-3",
"pos": [
51,
57
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "induced",
"pos": [
24,
30
],
"type": "Positive_regulation"
} |
||
9458352.s6 | Taken together, these studies suggest that IL-1 may kill ovarian NIH:OVCAR-3 tumor cells by inducing a blockade at G1/S of the cell cycle, down-regulating c-myc gene and inducing p53-dependent apoptosis. | ovarian | {
"name": "c-myc gene",
"pos": [
155,
164
]
} | {
"name": "OVCAR-3",
"pos": [
69,
75
]
} | decreased | cancerTOnormal | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "down-regulating",
"pos": [
139,
153
],
"type": "Negative_regulation"
} |
7913408.s8 | Ovarian carcinoma and breast carcinoma cells which are multiply drug resistant due to overexpression of P-glycoprotein are markedly less resistant to cryptophycin than they are to vinblastine, colchicine, and taxol. | ovarian | {
"name": "P-glycoprotein",
"pos": [
104,
117
]
} | {
"name": "Ovarian carcinoma",
"pos": [
0,
16
]
} | increased | unidentifiable | {
"name": "overexpression",
"pos": [
86,
99
],
"type": "Gene_expression"
} | {
"name": "overexpression",
"pos": [
86,
99
],
"type": "Positive_regulation"
} |
||
21539834.s3 | Cyclin E is overexpressed in breast, lung, skin, gastrointestinal, cervical, and ovarian cancers. | ovarian | {
"name": "Cyclin E",
"pos": [
0,
7
]
} | {
"name": "ovarian cancers",
"pos": [
81,
95
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpressed",
"pos": [
12,
24
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
12,
24
],
"type": "Positive_regulation"
} |
17285121.s7 | MonoHER suppressed DOX-dependent activation of the mitochondrial apoptotic pathway in normal and A2780 cells as illustrated by p53 accumulation and activation of caspase-9 and -3 cleavage. | ovarian | {
"name": "p53",
"pos": [
127,
129
]
} | {
"name": "A2780",
"pos": [
97,
101
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "accumulation",
"pos": [
131,
142
],
"type": "Positive_regulation"
} |
||
1541865.s3 | The levels of TAT and FDP were significantly higher in patients with ovarian cancer compared to the control group (both: p less than 0.01), and these levels were higher than in other gynecological malignancies. | ovarian | {
"name": "TAT",
"pos": [
14,
16
]
} | {
"name": "ovarian cancer",
"pos": [
69,
82
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "higher",
"pos": [
45,
50
],
"type": "Positive_regulation"
} |
1541865.s5 | TAT and FDP were increased following cancer dissemination, and the recovery of coagulative and fibrinolytic factors (TAT, FDP) with effective treatment was correlated to the prognosis for patients with ovarian cancer. | ovarian | {
"name": "TAT",
"pos": [
0,
2
]
} | {
"name": "ovarian cancer",
"pos": [
202,
215
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "increased",
"pos": [
17,
25
],
"type": "Positive_regulation"
} |
1541865.s5 | TAT and FDP were increased following cancer dissemination, and the recovery of coagulative and fibrinolytic factors (TAT, FDP) with effective treatment was correlated to the prognosis for patients with ovarian cancer. | ovarian | {
"name": "FDP",
"pos": [
8,
10
]
} | {
"name": "ovarian cancer",
"pos": [
202,
215
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "increased",
"pos": [
17,
25
],
"type": "Positive_regulation"
} |
17331422.s5 | Transfection of HER-2 siRNA was conducted with lipofectamine 2000 in ovarian carcinoma cell line SKOV3. | ovarian | {
"name": "HER-2 siRNA",
"pos": [
16,
26
]
} | {
"name": "ovarian carcinoma",
"pos": [
69,
85
]
} | increased | unidentifiable | {
"name": "Transfection",
"pos": [
0,
11
],
"type": "Gene_expression"
} | {
"name": "Transfection",
"pos": [
0,
11
],
"type": "Positive_regulation"
} |
||
12792888.s9 | Decreased p21Cip1 expression is related to several indicators of aggressiveness in ovarian adenocarcinomas and seems to be differentially regulated in LMP tumors and adenocarcinomas. | ovarian | {
"name": "p21Cip1",
"pos": [
10,
16
]
} | {
"name": "ovarian adenocarcinomas",
"pos": [
83,
105
]
} | decreased | normalTOcancer | observation | unidentifiable | {
"name": "expression",
"pos": [
18,
27
],
"type": "Gene_expression"
} | {
"name": "Decreased",
"pos": [
0,
8
],
"type": "Negative_regulation"
} |
14743504.s0 | Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. | ovarian | {
"name": "BRCA1 gene",
"pos": [
154,
163
]
} | {
"name": "ovarian neoplasms",
"pos": [
76,
92
]
} | decreased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "loss",
"pos": [
142,
145
],
"type": "Negative_regulation"
} |
||
14743504.s15 | These findings suggest that reduced expression of BRCA1 protein along with genetic and epigenetic changes of the BRCA1 gene play an important role in the development of sporadic ovarian carcinomas, particularly those of serous histology. | ovarian | {
"name": "BRCA1 protein",
"pos": [
50,
62
]
} | {
"name": "ovarian carcinomas",
"pos": [
178,
195
]
} | decreased | normalTOcancer | observation | unidentifiable | {
"name": "expression",
"pos": [
36,
45
],
"type": "Gene_expression"
} | {
"name": "reduced",
"pos": [
28,
34
],
"type": "Negative_regulation"
} |
14743504.s15 | These findings suggest that reduced expression of BRCA1 protein along with genetic and epigenetic changes of the BRCA1 gene play an important role in the development of sporadic ovarian carcinomas, particularly those of serous histology. | ovarian | {
"name": "BRCA1 gene",
"pos": [
113,
122
]
} | {
"name": "ovarian carcinomas",
"pos": [
178,
195
]
} | decreased | normalTOcancer | causality | unidentifiable | {
"name": "expression",
"pos": [
36,
45
],
"type": "Gene_expression"
} | {
"name": "reduced",
"pos": [
28,
34
],
"type": "Negative_regulation"
} |
20718682.s5 | Preoperatively, an elevated thyroglobulin (Tg) level, laboratory or clinical evidence of hyperthyroidism, or ultrasonography appearance of "struma pearl" should prompt referral to oncologist for surgical management of a possibly malignant ovarian teratoma. | ovarian | {
"name": "thyroglobulin",
"pos": [
28,
40
]
} | {
"name": "malignant ovarian teratoma",
"pos": [
229,
254
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "elevated",
"pos": [
19,
26
],
"type": "Positive_regulation"
} |
||
19486012.s6 | ZEB2 expression was negatively correlated with CDH1 expression in advanced stage samples, whereas ZEB2 knockdown in ovarian adenocarcinoma SKOV3 cells resulted in an increase in CDH1 expression. | ovarian | {
"name": "CDH1",
"pos": [
178,
181
]
} | {
"name": "ovarian adenocarcinoma",
"pos": [
116,
137
]
} | increased | unidentifiable | {
"name": "expression",
"pos": [
183,
192
],
"type": "Gene_expression"
} | {
"name": "increase",
"pos": [
166,
173
],
"type": "Positive_regulation"
} |
||
19486012.s6 | ZEB2 expression was negatively correlated with CDH1 expression in advanced stage samples, whereas ZEB2 knockdown in ovarian adenocarcinoma SKOV3 cells resulted in an increase in CDH1 expression. | ovarian | {
"name": "ZEB2",
"pos": [
98,
101
]
} | {
"name": "ovarian adenocarcinoma",
"pos": [
116,
137
]
} | decreased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "knockdown",
"pos": [
103,
111
],
"type": "Negative_regulation"
} |
||
9891239.s2 | p53 overexpression, identified by immunohistochemistry, and p53 mutations, identified by single-strand conformational polymorphism (SSCP) and DNA sequencing, have been described in ovarian cancers. | ovarian | {
"name": "p53",
"pos": [
0,
2
]
} | {
"name": "ovarian cancers",
"pos": [
181,
195
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpression",
"pos": [
4,
17
],
"type": "Gene_expression"
} | {
"name": "overexpression",
"pos": [
4,
17
],
"type": "Positive_regulation"
} |
9891239.s3 | p53 overexpression has been correlated with poor outcome for women with ovarian cancer in some studies. | ovarian | {
"name": "p53",
"pos": [
0,
2
]
} | {
"name": "ovarian cancer",
"pos": [
72,
85
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "overexpression",
"pos": [
4,
17
],
"type": "Gene_expression"
} | {
"name": "overexpression",
"pos": [
4,
17
],
"type": "Positive_regulation"
} |
15520877.s14 | No correlation could be seen between the histology of the ovarian tumours and the elevation of MMP-2/9 activity. | ovarian | {
"name": "MMP-2/9",
"pos": [
95,
101
]
} | {
"name": "ovarian tumours",
"pos": [
58,
72
]
} | increased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "elevation",
"pos": [
82,
90
],
"type": "Positive_regulation"
} |
||
15520877.s15 | More interestingly, however, MMP-9 expression and fibronectin concentration were significantly elevated and the activated forms of both MMP-9 and MMP-2 were more frequent in ovarian cancer patients who developed recurrent disease. | ovarian | {
"name": "MMP-9",
"pos": [
29,
33
]
} | {
"name": "ovarian cancer",
"pos": [
174,
187
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "expression",
"pos": [
35,
44
],
"type": "Gene_expression"
} | {
"name": "elevated",
"pos": [
95,
102
],
"type": "Positive_regulation"
} |
21119365.s6 | Angiopoietin-1 and Ang-2 levels were significantly elevated in serum samples of patients with ovarian carcinoma compared with healthy controls (P = 0.0005 and P < 0.0005, respectively). | ovarian | {
"name": "Ang-2",
"pos": [
19,
23
]
} | {
"name": "ovarian carcinoma",
"pos": [
94,
110
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "levels",
"pos": [
25,
30
],
"type": "Gene_expression"
} | {
"name": "elevated",
"pos": [
51,
58
],
"type": "Positive_regulation"
} |
21119365.s6 | Angiopoietin-1 and Ang-2 levels were significantly elevated in serum samples of patients with ovarian carcinoma compared with healthy controls (P = 0.0005 and P < 0.0005, respectively). | ovarian | {
"name": "Angiopoietin-1",
"pos": [
0,
13
]
} | {
"name": "ovarian carcinoma",
"pos": [
94,
110
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "levels",
"pos": [
25,
30
],
"type": "Gene_expression"
} | {
"name": "elevated",
"pos": [
51,
58
],
"type": "Positive_regulation"
} |
21119365.s7 | In addition, Ang-2 levels were significantly higher in patients with ovarian carcinoma compared with patients with benign (P < 0.0005) or borderline ovarian tumors (P = 0.011). | ovarian | {
"name": "Ang-2",
"pos": [
13,
17
]
} | {
"name": "borderline ovarian tumors",
"pos": [
138,
162
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "levels",
"pos": [
19,
24
],
"type": "Gene_expression"
} | {
"name": "higher",
"pos": [
45,
50
],
"type": "Positive_regulation"
} |
22001143.s19 | Anti-androgen use early in the course of ovarian cancer is more likely to be effective as these data suggest that androgen receptor expression decreases with exposure to chemotherapy and this may explain the low response rates seen in clinical trials of patients heavily pre-treated with multiple courses of chemotherapy. | ovarian | {
"name": "androgen receptor",
"pos": [
114,
130
]
} | {
"name": "ovarian cancer",
"pos": [
41,
54
]
} | decreased | unidentifiable | {
"name": "expression",
"pos": [
132,
141
],
"type": "Gene_expression"
} | {
"name": "decreases",
"pos": [
143,
151
],
"type": "Negative_regulation"
} |
||
11014575.s0 | Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions. | ovarian | {
"name": "Tn",
"pos": [
176,
177
]
} | {
"name": "epithelial ovarian carcinoma",
"pos": [
121,
148
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "expression",
"pos": [
201,
210
],
"type": "Gene_expression"
} | {
"name": "up-regulated",
"pos": [
163,
174
],
"type": "Positive_regulation"
} |
11014575.s0 | Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions. | ovarian | {
"name": "Sialyl Tn antigen",
"pos": [
183,
199
]
} | {
"name": "epithelial ovarian carcinoma",
"pos": [
121,
148
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "expression",
"pos": [
201,
210
],
"type": "Gene_expression"
} | {
"name": "up-regulated",
"pos": [
163,
174
],
"type": "Positive_regulation"
} |
11014575.s10 | Ovarian carcinoma cells in effusions show up-regulation of Tn and Sialyl Tn, possibly representing a transient phenotypic alteration facilitating metastasis. | ovarian | {
"name": "Sialyl Tn",
"pos": [
66,
74
]
} | {
"name": "Ovarian carcinoma",
"pos": [
0,
16
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "up-regulation",
"pos": [
42,
54
],
"type": "Positive_regulation"
} |
11014575.s10 | Ovarian carcinoma cells in effusions show up-regulation of Tn and Sialyl Tn, possibly representing a transient phenotypic alteration facilitating metastasis. | ovarian | {
"name": "Tn",
"pos": [
59,
60
]
} | {
"name": "Ovarian carcinoma",
"pos": [
0,
16
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "up-regulation",
"pos": [
42,
54
],
"type": "Positive_regulation"
} |
21436696.s5 | Significantly decreased, or complete loss of, protein expression of the TSLC1 gene was observed in 59% ovarian carcinomas, 45% borderline tumors, and 7% cystadenomas, but in none of the normal ovaries (0%). | ovarian | {
"name": "TSLC1 gene",
"pos": [
72,
81
]
} | {
"name": "ovarian carcinomas",
"pos": [
103,
120
]
} | decreased | normalTOcancer | observation | unchanged | {
"name": "expression",
"pos": [
54,
63
],
"type": "Gene_expression"
} | {
"name": "loss",
"pos": [
37,
40
],
"type": "Negative_regulation"
} |
21436696.s6 | In ovarian carcinomas, decreased TSLC1 expression was significantly correlated with lymph node metastasis (pN, P = 0.001), distant metastasis (pM, P = 0.028), and more advanced International Federation of Gynecology and Obstetrics stages (P = 0.008). | ovarian | {
"name": "TSLC1",
"pos": [
33,
37
]
} | {
"name": "ovarian carcinomas",
"pos": [
3,
20
]
} | decreased | normalTOcancer | causality | unidentifiable | {
"name": "expression",
"pos": [
39,
48
],
"type": "Gene_expression"
} | {
"name": "decreased",
"pos": [
23,
31
],
"type": "Negative_regulation"
} |
21436696.s7 | By univariate survival analysis on the ovarian carcinoma cohorts, decreased TSLC1 protein expression was significantly associated with shortened patient survival (mean: 26.9 months in tumors with complete loss of TSLC1 vs 63.1 months in tumors with significantly decreased TSLC1 vs 94.3 months in tumors with normal levels of TSLC1; P < 0.001). | ovarian | {
"name": "TSLC1",
"pos": [
273,
277
]
} | {
"name": "ovarian carcinoma",
"pos": [
39,
55
]
} | decreased | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "decreased",
"pos": [
263,
271
],
"type": "Negative_regulation"
} |
||
21436696.s7 | By univariate survival analysis on the ovarian carcinoma cohorts, decreased TSLC1 protein expression was significantly associated with shortened patient survival (mean: 26.9 months in tumors with complete loss of TSLC1 vs 63.1 months in tumors with significantly decreased TSLC1 vs 94.3 months in tumors with normal levels of TSLC1; P < 0.001). | ovarian | {
"name": "TSLC1 protein",
"pos": [
76,
88
]
} | {
"name": "ovarian carcinoma",
"pos": [
39,
55
]
} | decreased | unidentifiable | {
"name": "expression",
"pos": [
90,
99
],
"type": "Gene_expression"
} | {
"name": "decreased",
"pos": [
66,
74
],
"type": "Negative_regulation"
} |
||
21436696.s9 | Decreased protein expression of the TSLC1 gene might be important in conferring a more aggressive behavior in ovarian carcinoma. | ovarian | {
"name": "TSLC1 gene",
"pos": [
36,
45
]
} | {
"name": "ovarian carcinoma",
"pos": [
110,
126
]
} | decreased | normalTOcancer | causality | unidentifiable | {
"name": "expression",
"pos": [
18,
27
],
"type": "Gene_expression"
} | {
"name": "Decreased",
"pos": [
0,
8
],
"type": "Negative_regulation"
} |
21300758.s1 | Src is an attractive target because it is overexpressed in a number of malignancies, including ovarian cancer. | ovarian | {
"name": "Src",
"pos": [
0,
2
]
} | {
"name": "ovarian cancer",
"pos": [
95,
108
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpressed",
"pos": [
42,
54
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
42,
54
],
"type": "Positive_regulation"
} |
14961570.s0 | Genetic downregulation of pregnancy-associated plasma protein-A (PAPP-A) by bikunin reduces IGF-I-dependent Akt and ERK1/2 activation and subsequently reduces ovarian cancer cell growth, invasion and metastasis. | ovarian | {
"name": "ERK1/2",
"pos": [
116,
121
]
} | {
"name": "ovarian cancer",
"pos": [
159,
172
]
} | decreased | cancerTOnormal | observation | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "reduces",
"pos": [
84,
90
],
"type": "Negative_regulation"
} |
21789787.s5 | NTN1 was found overexpressed in 76% of ovarian cancer specimens (13/17) as compared to normal (0/10, p<0.004)and benign (1/8, p<0.008) samples. | ovarian | {
"name": "NTN1",
"pos": [
0,
3
]
} | {
"name": "ovarian cancer",
"pos": [
39,
52
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpressed",
"pos": [
15,
27
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
15,
27
],
"type": "Positive_regulation"
} |
21789787.s8 | Here,we demonstrated that NTN1 may be involved in ovarian cancer as the expression of NTN1 mRNA is strongly upregulated in ovarian malignant tumors but not in benign tumors. | ovarian | {
"name": "NTN1 mRNA",
"pos": [
86,
94
]
} | {
"name": "ovarian cancer",
"pos": [
50,
63
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "expression",
"pos": [
72,
81
],
"type": "Gene_expression"
} | {
"name": "upregulated",
"pos": [
108,
118
],
"type": "Positive_regulation"
} |
21789787.s9 | The fact that increased NTN1 is specifically observed in cancerous tissues indicates that NTN1 may represent a novel candidate biomarker for ovarian cancer. | ovarian | {
"name": "NTN1",
"pos": [
24,
27
]
} | {
"name": "ovarian cancer",
"pos": [
141,
154
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "increased",
"pos": [
14,
22
],
"type": "Positive_regulation"
} |
20388850.s5 | Quantitative reverse transcription-PCR and Western blot analyses showed that GRB7 and GRB7v were frequently upregulated in ovarian cancer samples. | ovarian | {
"name": "GRB7v",
"pos": [
86,
90
]
} | {
"name": "ovarian cancer",
"pos": [
123,
136
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "upregulated",
"pos": [
108,
118
],
"type": "Positive_regulation"
} |
20388850.s5 | Quantitative reverse transcription-PCR and Western blot analyses showed that GRB7 and GRB7v were frequently upregulated in ovarian cancer samples. | ovarian | {
"name": "GRB7",
"pos": [
77,
80
]
} | {
"name": "ovarian cancer",
"pos": [
123,
136
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "upregulated",
"pos": [
108,
118
],
"type": "Positive_regulation"
} |
20388850.s6 | The overexpressed GRB7 (P = 0.009) and GRB7v (P = 0.017) were significantly correlated with high-grade ovarian cancer. | ovarian | {
"name": "GRB7",
"pos": [
18,
21
]
} | {
"name": "ovarian cancer",
"pos": [
103,
116
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpressed",
"pos": [
4,
16
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
4,
16
],
"type": "Positive_regulation"
} |
20388850.s7 | Immunohistochemical analysis on ovarian cancer tissue array confirmed that the upregulated GRB7 was significantly correlated with high-grade ovarian cancer (P = 0.001). | ovarian | {
"name": "GRB7",
"pos": [
91,
94
]
} | {
"name": "ovarian cancer",
"pos": [
32,
45
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "upregulated",
"pos": [
79,
89
],
"type": "Positive_regulation"
} |
20388850.s11 | Our studies implicate that the overexpressed GRB7 and GRB7v are associated with high-grade tumors and exert distinct tumorigenic functions through regulating different signaling pathways in ovarian cancer cells. | ovarian | {
"name": "GRB7",
"pos": [
45,
48
]
} | {
"name": "ovarian cancer",
"pos": [
190,
203
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "overexpressed",
"pos": [
31,
43
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
31,
43
],
"type": "Positive_regulation"
} |
20388850.s11 | Our studies implicate that the overexpressed GRB7 and GRB7v are associated with high-grade tumors and exert distinct tumorigenic functions through regulating different signaling pathways in ovarian cancer cells. | ovarian | {
"name": "GRB7v",
"pos": [
54,
58
]
} | {
"name": "ovarian cancer",
"pos": [
190,
203
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "overexpressed",
"pos": [
31,
43
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
31,
43
],
"type": "Positive_regulation"
} |
15523695.s0 | Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. | ovarian | {
"name": "progelatinase",
"pos": [
78,
90
]
} | {
"name": "ovarian cancer",
"pos": [
40,
53
]
} | increased | normalTOcancer | causality | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "activation",
"pos": [
64,
73
],
"type": "Positive_regulation"
} |
15523695.s4 | We report that MMP-7 is overexpressed in ovarian cancer cell lines and EOC surgical specimens. | ovarian | {
"name": "MMP-7",
"pos": [
15,
19
]
} | {
"name": "ovarian cancer",
"pos": [
41,
54
]
} | increased | normalTOcancer | observation | unchanged | {
"name": "overexpressed",
"pos": [
24,
36
],
"type": "Gene_expression"
} | {
"name": "overexpressed",
"pos": [
24,
36
],
"type": "Positive_regulation"
} |
15523695.s5 | DOV13 cells incubated with active rhMMP-7 significantly increased cellular invasion and proMMP-2 activation. | ovarian | {
"name": "proMMP-2",
"pos": [
88,
95
]
} | {
"name": "DOV13",
"pos": [
0,
4
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "activation",
"pos": [
97,
106
],
"type": "Positive_regulation"
} |
15523695.s8 | TIMP-2 or the generic MMP inhibitor-GM6001 inhibited both the activation of proMMP-2 and the increased invasion of DOV13 cells promoted by rhMMP-7. | ovarian | {
"name": "proMMP-2",
"pos": [
76,
83
]
} | {
"name": "DOV13",
"pos": [
115,
119
]
} | increased | normalTOcancer | observation | unidentifiable | {
"name": "\nNone\n",
"pos": null,
"type": null
} | {
"name": "activation",
"pos": [
62,
71
],
"type": "Positive_regulation"
} |